Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme

By sjmartinez • February 1, 2023

Dougados M, Charles-Schoeman C, Szekanecz Z, Giles JT, Ytterberg SR, Bhatt DL, Koch GG, Vranic I, Wu J, Wang C, Kwok K, Menon S, Connell CA, Yndestad A, Rivas JL, Buch MH. Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme. Ann Rheum Dis. 2023 Jan 31:ard-2022-223406. doi: 10.1136/ard-2022-223406. Epub ahead of print. PMID: 36720582.

Tags: Antirheumatic Agents, Arthritis, cardiovascular diseases, Publications, Rheumatoid, Rheumatology

Dupilumab for bullous pemphigoid: Umbrella review of systematic reviews and meta-analyses

Thapa M, Green B, Kasperkiewicz M. Dupilumab for bullous pemphigoid: Umbrella review of systematic reviews and meta-analyses. JAAD Int. 2025 Oct 18;24:172-176. doi: 10.1016/j.jdin.2025.10.004. PMID:[...]

Metabolic Acidosis in Chronic Alcoholism: When It’s Not Just Diabetic Ketoacidosis

Li R, Han J, Sidhu H. Metabolic Acidosis in Chronic Alcoholism: When It's Not Just Diabetic Ketoacidosis. Cureus. 2025 Nov 11;17(11):e96632. doi: 10.7759/cureus.96632. PMID: 41393585;[...]

Immunomodulatory Microneedle Patch for Cardiac Repair in Rodent and Porcine Models of Myocardial Infarction

Huang K, Zhu D, Soto J, Hu S, Fang J, Huang J, Zhang X, Li J, Li Y, Tasoudis P, Liu S, Mei X, Hoffman[...]